Cencora, Inc. (COR) — Analysis Summary
Cencora, Inc. (COR) has a market cap of $61.80B with year-over-year revenue growth of +9.3%. Net margin stands at 0.5%. The stock trades at a P/E ratio of 23.5.
Key Takeaways
- Revenue changed +9.3% year-over-year
- Net margin of 0.5%
- P/E ratio of 23.5
Compared to other companies in the WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES sector, COR posted revenue growth of +9.3% and trades at a P/E of 23.5.
Cencora, Inc. (COR)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.93x — current liabilities exceed current assets
D/E at 3.6x — high financial leverage
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Sector
WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Employees
51,000
Headquarters
CONSHOHOCKEN, PA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$2.40
Dividend Yield
0.74%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.